Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Wishing you a colorful Día de los Muertos. Remembering my grandmother, in particular, a zoology professor who sparked my penchant for all things biological. Her dissertation was on shrimp chromatophores, I believe.
The need-to-know this morning
- UniQure said the Food and Drug Administration accepted the marketing application for its AMT-130 gene therapy to treat Huntington’s disease. The approval decision date is May 1, 2027. The FDA is “tentatively planning” an advisory committee meeting to review the AMT-130 data, the company said.
Scant evidence for a next-gen, destination IVF business
A fertility treatment framed as a way to rewind the biological clock has spawned an international medical tourism business — with precious little evidence to back it up. An eight-month STAT investigation found clinics and middlemen marketing mitochondrial replacement, or “three-parent IVF,” to older women willing to spend tens of thousands of dollars for a shot at a genetically related child.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.
Already have an account? Log in
To read the rest of this story subscribe to STAT+.